CDKN2A and melanoma: Thus, Lelliott and collaborators used a syngeneic BRAF V600E Cdkn2a-/-Pten-/- melanoma model and demonstrated that a triple therapy including BRAF, MEK, and CDK4/6 inhibitors led to an immediate tumor regression and improved mice survival, compared to the respective monotherapies [250].